Towards A Biomarker To Predict Survival in Advanced Prostate Cancer

According to the results of a study published in the Journal of Clinical Oncology a bone scan index (BSI) can assess response to treatment and predict survival in metastatic hormone-refractory prostate cancer. Men who have castrate resistant or metastatic hormone-refractory prostate cancer that no longer responds to hormonal therapy and has spread to distant sites [...]

On the Horizon – TOK-001 (Galeterone)

Tokai, a Cambridge, MA based Pharmaceutical company, just presented a promising set of Phase I data pointing to the early efficacy of its "triple whammy" pill for castration-resistant prostate cancer, TOK-001 or galeterone. In their phase 1 trial the PSA levels in about half of the 49 men in the dose-ranging study declined 30% or [...]

A New Genetic Technique Predicts Prostate Cancer Relapse

According to a study published online May 9 in The American Journal of Pathology copy number variations (CNV) in both malignant and benign prostate tissue is predictive of prostate cancer relapse. The research performed at the University of Pittsburgh School of Medicine by Yan P. Yu, M.D. and colleagues evaluated whether CNV of the genomes [...]

Good News – We Have Made It Over Another Funding Hurdle for the Department of Defense Medical Research Program for Fiscal 2013

Yesterday May 16, 2012, the House Appropriations Committee released their draft committee report to accompany the FY13 Defense Appropriations Act. This draft included the CDMRP requested budget for 2013. The good news is that the ask includes $80 million dollars for the Prostate Cancer Research Program. Although this is the same amount prostate cancer received [...]

New Data Indicates That Provenge Works Best In Men With Lower PSA Scores

Today, May 16, 2012, Dendreon, the makers of Provenge, disclosed a new analysis of data of its pivotal 512-patient study of men with castrate resistant prostate cancer who received sipuleucel-T (Provenge). The new analysis separated the men in the study into four quartiles based on their prostate-specific antigen (PSA) scores. The initial design of the [...]

Go to Top